Lakhani, S, Selby, P, Bliss, JM et al. (3 more authors) (1990) Chemotherapy for malignant melanoma: Combinations and high doses produce more responses without survival benefit. British Journal of Cancer, 61 (2). pp. 330-334. ISSN 0007-0920
Abstract
In a consecutive series of studies, 164 patients with symptomatic and/or visceral metastatic malignant melanoma were treated with single agent vindesine, high dose melphalan with autologous bone marrow transplantation (ABMT), high dose BCNU with ABMT or the BOLD (bleomycin, vincristine, CCNU and DTIC) combination. The high dose treatments and the combination chemotherapy resulted in significantly higher response rates but no prolongation of survival. Factors associated with longer survival included the absence of visceral metastases, the absence of bulky disease and good performance status. For all treatments, life table estimates of survival at 1 and 2 years were only 10% and 4% respectively.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | (c) 1990, Macmillan Press. Reproduced in accordance with the publisher's self-archiving policy under a Creative Commons Attribution Non-Commercial Share Alike License. |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 21 Jun 2016 13:52 |
Last Modified: | 21 Jun 2016 13:52 |
Published Version: | http://dx.doi.org/10.1038/bjc.1990.65 |
Status: | Published |
Publisher: | Cancer Research UK/Macmillan Press |
Identification Number: | 10.1038/bjc.1990.65 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:100586 |